We are excited to announce that Avivo has been selected as one of the 150 companies out of over 3600 applicants joining the NATO DIANA 2026 Challenge Programme Cohort! Our blood type conversion technology was chosen under the Human Resilience & Biotechnologies call. Over the next six months, we will work closely with the NATO DIANA Accelerator Site, INCIBE, and engage with DIANA’s network of experts, mentors, and test centres to refine our solution and shape it to operational needs.
The programme gives us the opportunity to deepen our technological readiness, strengthen our understanding of defence and dual-use markets, and access to world-class testing infrastructure to help validate our solution. We are particularly looking forward to engaging with end-users, gaining early feedback, and building a pathway towards adoption by NATO and Allies on our journey to realize a world without blood type constraints in blood transfusion and organ transplantation.
Discover the full list of innovators and their solutions here:
https://www.diana.nato.int/about-diana/2026-cohort-of-companies.html
